The global PARP inhibitor biomarkers market is expected to grow at a CAGR of 8.6% during the forecast period. Market growth is being driven by the increasing adoption of precision oncology, rising prevalence of hereditary and advanced cancers, growing utilization of companion diagnostics, and expanding use of PARP inhibitor therapies across multiple cancer indications.
The global point of care (PoC) lipid test market is projected to grow at a CAGR of 5.0% from 2025 to 2033, driven by the rising burden of cardiovascular and metabolic disorders, increasing preference for early disease detection, and growing demand for decentralized diagnostics. PoC lipid testing devices enable rapid, on-site measurement of cholesterol, triglycerides, HDL, and LDL levels, facilitating timely diagnosis and intervention in clinical and non-clinical settings. As healthcare systems continue to shift toward preventive care and patient-centric models, PoC lipid testing is becoming integral to routine screenings, particularly in primary care clinics, pharmacies, mobile units, and community health programs.
The home sleep screening devices market is projected to grow at a CAGR of 7.2% during the forecast period 2025 to 2033, driven by increasing awareness of sleep disorders, technological innovations in compact monitoring systems, and the rising preference for non-invasive and accessible home-based diagnostics. Home sleep screening devices, including wearable and non-wearable types, offer an affordable and patient-centric alternative to in-lab polysomnography, enabling continuous data tracking for accurate sleep analysis.
The bovine tuberculosis diagnosis market is expected to grow at a CAGR of 7.7% during the forecast period of 2025 to 2033. Bovine tuberculosis (bTB) is a chronic disease among cattle caused by the bacterium Mycobacterium bovis, closely related to the bacteria that causes tuberculosis in humans. This disease has a significant impact on livestock worldwide due to its ability to spread rapidly among herds and its potential for transmission to humans, primarily through unpasteurized milk and direct contact.
The gas exchange pulmonary function testing market is expected to grow at a CAGR of 6.0% during the forecast period of 2025 to 2033. Gas exchange pulmonary function testing market comprises diagnostic tools used to assess the respiratory function by measuring gas transfer in the lungs. This market has gained prominence due to the rising prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and pulmonary fibrosis. These tests help in diagnosing the extent of lung damage, monitoring disease progression, and guiding treatment decisions.
The femtech market is expected to grow at a CAGR of 12.7% during the forecast period of 2025 to 2033. Femtech, or female technology, encompasses a range of products, software, and diagnostics that focus on women's health, including reproductive health, pregnancy and nursing care, pelvic and uterine healthcare, menstrual health, and sexual wellness. The market is gaining traction as it addresses long-underrepresented areas in healthcare through the integration of technology, medical insights, and consumer-centric approaches.
The automotive fault diagnostic scan tools market is expected to grow at a CAGR of 6.5% during the forecast period of 2025 to 2033. Automotive fault diagnostic scan tools market encompasses devices and software used for identifying issues within vehicle electronic systems. These tools are essential in the automotive industry, aiding technicians in diagnosing and repairing faults efficiently. The market is influenced by the increasing complexity of automotive electronics, the growth in automotive production and ownership, and regulatory pressures for lower emissions and safer vehicles.
The rabies diagnostics market is expected to grow at a CAGR of 5.1% during the forecast period of 2025 to 2033, due to several critical factors driving demand for effective diagnostic solutions. Key conclusions indicate that the market is heavily influenced by the rising incidence of rabies, advancements in diagnostic technologies, and increased funding for rabies control initiatives.
The genetic testing market is expected to grow at a CAGR of 22.7% during the forecast period of 2025 to 2033, driven by advancements in technology, increasing awareness of genetic disorders, and the rising demand for personalized medicine. Genetic testing involves analyzing DNA to identify changes or mutations that may lead to genetic disorders or predispositions to certain health conditions. In 2025, the market generated substantial revenue, largely due to the widespread adoption of next-generation sequencing (NGS) and the growing prevalence of genetic diseases.
The neurovascular catheters market is expected to grow at a CAGR of 7.25% during the forecast period of 2025 to 2033. The nuanced analysis reveals the significance of technological advancements, the increasing prevalence of neurological disorders, and evolving applications in driving market dynamics. As the market evolves, a strategic approach to address regulatory challenges and capitalize on emerging opportunities will be crucial for sustained growth and competitiveness.
The diagnostics market includes instruments, reagents, test kits, software and related services used to detect diseases, assess patient health and support treatment decisions. Major areas include clinical chemistry, molecular diagnostics, immunodiagnostics, hematology, microbiology, genetic testing, companion diagnostics and point-of-care testing. Hospitals, diagnostic laboratories, research institutions, physician offices and home-care users represent the market’s major customers.
The global clinical diagnostics market is projected to increase from USD 87.99 billion in 2025 to USD 150.30 billion by 2035, registering a CAGR of 5.50% from 2026 to 2035. This forecast represents clinical diagnostics; individual segments such as molecular, digital and point-of-care diagnostics may record different growth rates.
The increasing prevalence of cancer, diabetes, cardiovascular disorders and infectious diseases is a major market growth driver. Aging populations and rising awareness of preventive healthcare are increasing the demand for routine testing and early disease detection. Healthcare providers are also using diagnostic tests to monitor treatment response, determine disease risk and select suitable therapies.
Molecular diagnostics is an important growth area because it can identify genetic material, pathogens and disease-related biomarkers with high accuracy. Polymerase chain reaction, next-generation sequencing and other molecular testing technologies are increasingly used in oncology, infectious disease testing and inherited disorder screening. Companion diagnostics are also gaining importance because they help identify patients who are likely to benefit from specific targeted medicines.
Point-of-care and home-based testing represent another major trend. Portable diagnostic systems provide results close to the patient, reducing the time between sample collection and treatment decisions. Demand is growing for rapid tests, connected glucose monitors and other decentralized testing solutions. However, laboratory-based systems remain important for complex tests, high sample volumes and confirmatory analysis.
Artificial intelligence, laboratory automation and digital connectivity are changing diagnostic workflows. Automated sample handling can improve laboratory productivity and reduce manual errors. AI-supported platforms help professionals analyze test results and identify patterns, while connected diagnostic systems enable data transfer between laboratories, hospitals and electronic health records.
Market restraints include high equipment costs, strict approval requirements, reimbursement limitations and shortages of trained laboratory professionals. Differences in test quality and healthcare access may also limit adoption in developing markets. Diagnostic companies must address data security, result accuracy and system compatibility when introducing digital platforms.
North America leads the market due to developed laboratory infrastructure, high testing volumes and early adoption of advanced technologies. Europe maintains strong demand supported by established healthcare systems. Asia-Pacific is expected to offer significant growth opportunities through 2035 due to increasing healthcare expenditure, expanding diagnostic networks and rising disease screening in China, India and Southeast Asia.
Acute Market Reports provides diagnostics market research covering market size, product and technology analysis, disease applications, end users, competitive developments, regional opportunities and forecasts through 2035. These reports support diagnostic companies, laboratories, healthcare providers and investors in making informed business decisions.